Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inmune Bio Inc (NQ: INMB ) 7.830 -0.160 (-2.00%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 159,676 Open 7.950 Bid (Size) 7.820 (47) Ask (Size) 7.830 (2) Prev. Close 7.990 Today's Range 7.700 - 8.010 52wk Range 6.500 - 14.74 Shares Outstanding 17,703,692 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial June 27, 2024 From INmune Bio, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 20, 2024 Via Benzinga Performance YTD -30.21% -30.21% 1 Month -12.51% -12.51% 3 Month -24.42% -24.42% 6 Month -38.97% -38.97% 1 Year -17.67% -17.67% More News Read More INmune Bio Inc. to Join Russell 3000® Index May 30, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio: Q4 Earnings Insights March 28, 2024 Via Benzinga A Preview Of INmune Bio's Earnings March 27, 2024 Via Benzinga INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 May 07, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years April 30, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer April 29, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 25, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay April 23, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering April 22, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 April 08, 2024 From INmune Bio, Inc. Via GlobeNewswire INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 March 28, 2024 Via InvestorPlace Earnings Scheduled For March 28, 2024 March 28, 2024 Via Benzinga INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 March 26, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy March 13, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™ March 05, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 12, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024 February 06, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program January 30, 2024 From INmune Bio, Inc. Via GlobeNewswire Why Is Elevai Labs (ELAB) Stock Up Today? January 16, 2024 Via InvestorPlace Why Elevai Labs Stock Is Trading Higher January 16, 2024 Via Benzinga ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology January 16, 2024 From Elevai Labs Inc. Via GlobeNewswire INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer January 02, 2024 From INmune Bio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
